Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241

Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241

PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical needs in non-small cell lung cancer ("NSCLC") CASTRES, France, June 16, 2025 /PRNewswire/ --...

Farizon SV Combi Released in Hong Kong and First Batch of 1,000 Taxis Delivered

Farizon SV Combi Released in Hong Kong and First Batch of 1,000 Taxis Delivered

HONG KONG, June 13, 2025 /PRNewswire/ -- Farizon New Energy Commercial Vehicle showcased multiple models at the Geely Holding Group exhibition booth during the 2025 International Automotive & Supply Chain Expo (Hong Kong), and held the...

DeepL first to deploy NVIDIA DGX SuperPOD with DGX GB200 systems in Europe, advancing Language AI with powerful generative features and enhanced user experience

DeepL first to deploy NVIDIA DGX SuperPOD with DGX GB200 systems in Europe, advancing Language AI with powerful generative features and enhanced user experience

DeepL's Language AI platform can now translate the entire web into another language in just 18.5 days – down from 194 days PARIS, June 11, 2025 /PRNewswire/ -- DeepL, a leading global Language AI company, today announced the deployment of an NVIDIA...

JediCare Medical has announced successful completion of its first-in-human feasibility study of the world's first-of-its-kind Pulmonary Nodule Percutaneous Sphere Resection

JediCare Medical has announced successful completion of its first-in-human feasibility study of the world's first-of-its-kind Pulmonary Nodule Percutaneous Sphere Resection

SHANGHAI, April 30, 2025 /PRNewswire/ -- JediCare Medical Technology Co., Ltd. a Shanghai, China based company ("the Company"), jointly with West China Hospital of Sichuan University, recently announced the successful completion of first-in-human...

Global Times: Xi's pre-Spring Festival visits to the grassroots reflect 'people-first' philosophy

Global Times: Xi's pre-Spring Festival visits to the grassroots reflect 'people-first' philosophy

BEIJING, Jan. 24, 2025 /PRNewswire/ -- As the Year of the Snake draws near, Xi Jinping, general secretary of the Communist Party of China (CPC) Central Committee, on Thursday inspected Shenyang, capital city of Northeast China's Liaoning Province....

Fibocom Debuts Industry-first "AI Buddy" Set to Expand AI-enhanced Interaction to Consumer-centric Scenarios at CES 2025

Fibocom Debuts Industry-first "AI Buddy" Set to Expand AI-enhanced Interaction to Consumer-centric Scenarios at CES 2025

LAS VEGAS, Jan. 9, 2025 /PRNewswire/ -- Fibocom (Stock code: 300638), a global leading provider of AIoT solutions and wireless communication modules, debuts the industry-first "AI Buddy" catering to bring an AI-enhanced real-time interaction to...

A New Hope for Atrial Fibrillation Patients with Breakthrough Catheter Technology

A New Hope for Atrial Fibrillation Patients with Breakthrough Catheter Technology

BTL, a leader in medical innovation, is proud to announce a major milestone: the successful treatment of the first patients suffering from atrial fibrillation (AF) in a groundbreaking study using a next-generation catheter designed to improve the...

HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease

HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease

HL192 (ATH-399A) was well tolerated with no major safety issues in any of the 76 participants. No serious treatment related adverse events were reported and such findings were proportional between placebo and dosed groups. PK results support once a...

menu
menu